MP11-Reumatología
Medicina de Precisión / IBS-MP11
OBJETIVO DEL GRUPO: Profundizar en la patogenia de la artritis reumatoide. Bases Genético-moleculares de la artritis reumatoide: identificación de marcadores genéticos de predisposición y pronóstico. Destacar su participación en Proyectos Nacionales e Internacionales de financiación competitiva, Colaboración en diferentes proyectos con la SER/FER y de la SAR/FAR, Colaboración en proyectos de financiación competitiva con el Instituto de Parasitología y Biomedicina López-Neyra (CSIC), con Centro de Genómica e Investigación Oncológica (GENyO) y con la Universidad de Granada.
Líneas de investigación
- Biomarcadores de pronóstico y evolución clínica
- Expresión génica en enfermedades autoinmunes
- Factores de respuesta a las terapias biológicas
- Factores pronósticos de evolución y respuesta terapéutica
- Morbilidad cardiovascular
- Polimorfismos en artritis reumatoide
- Riesgo cardiovascular en enfermedades reumatológicas autoinmunes
Redes de investigación
- RIER - Investigación en Inflamación y Enfermedades Reumáticas
ISMAEL FRANCISCO AOMAR MILLAN
INMACULADA JIMENEZ MOLEON
PILAR MORALES GARRIDO
ENRIQUE RAYA ALVAREZ
JUAN SALVATIERRA OSSORIO
RICARDO SANCHEZ PARERA
Image in Osteology
REVISTA DE OSTEOPOROSIS Y METABOLISMO MINERAL, 2023;
Molecular typing of canine parvovirus type 2 by VP2 gene sequencing and restriction fragment length polymorphism in affected dogs from Egypt
FRONTIERS IN MICROBIOLOGY, 2023;
FI:6,064; Q1
Characteristics and clinical outcome in 312 patients with moderate to severe pneumonia due to SARS-COV-2 and hyperinflammation treated with anakinra and corticosteroids: A retrospective cohort study
PLOS ONE, 2023;
FI:3,7; Q2
Pregnancy outcomes in 1869 pregnancies in a large cohort from the Spanish Society of Rheumatology Lupus Register (RELESSER)
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2023;
FI:5; Q2
Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study
ADVANCES IN THERAPY, 2023;
FI:3,8; Q3
Hospitalization and mortality from COVID-19 of patients with rheumatic inflammatory diseases in Andalusia
REUMATOLOGIA CLINICA, 2022;
Dose-Dependent Effect of Melatonin on BAT Thermogenesis in Zucker Diabetic Fatty Rat: Future Clinical Implications for Obesity
ANTIOXIDANTS, 2022;
FI:7,675; D1
Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients
RHEUMATOLOGY, 2022;
FI:7,046; Q1
Biologic therapy in refractory neurobehcet’s disease: a multicentre study of 41 patients and literature review
RHEUMATOLOGY, 2022;
FI:7,046; Q1
Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
MEDICINA CLINICA, 2022;
FI:3,2; Q2
A new molecular classification to drive precision treatment strategies in primary Sjogren’s syndrome.
NATURE COMMUNICATIONS, 2021;
FI:14,919; D1
Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases.
ARTHRITIS & RHEUMATOLOGY, 2021;
FI:10,995; D1
Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study
INTERNAL AND EMERGENCY MEDICINE, 2021;
FI:3,397; Q2
Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply..
INTERNAL AND EMERGENCY MEDICINE, 2021;
FI:3,397; Q2
Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021;
FI:4,473; Q2
Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients
RHEUMATOLOGY, 2020;
FI:5,606; Q1
Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER)
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2020;
FI:4,751; Q1
Bacteremia in Systemic Lupus Erythematosus in Patients from a Spanish Registry: Risk Factors, Clinical and Microbiological Characteristics, and Outcomes
JOURNAL OF RHEUMATOLOGY, 2020;
FI:3,35; Q2
Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality
LUPUS, 2020;
FI:2,251; Q3
Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the RELESSER registry)
LUPUS, 2020;
FI:2,251; Q3
Identification of a 3 ‘-Untranslated Genetic Variant of RARB Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study
ARTHRITIS & RHEUMATOLOGY, 2019;
FI:9,002; D1
Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behcet’s Disease: National Multicenter Study of 177 Cases
ARTHRITIS & RHEUMATOLOGY, 2019;
FI:9,002; D1
Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2019;
FI:5,072; Q1
Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept
PLOS ONE, 2019;
FI:2,776; Q2
Molecular Characterization of Monocyte Subsets Reveals Specific and Distinctive Molecular Signatures Associated With Cardiovascular Disease in Rheumatoid Arthritis
FRONTIERS IN IMMUNOLOGY, 2019;
FI:4,716; Q2
Cross-phenotype analysis of Immunochip data identifies KDM4C as a relevant locus for the development of systemic vasculitis
ANNALS OF THE RHEUMATIC DISEASES, 2018;
FI:12,35; D1
Association of a rare variant of the TNFSF13B gene with susceptibility to Rheumatoid Arthritis and Systemic Lupus Erythematosus
SCIENTIFIC REPORTS, 2018;
FI:4,122; Q1
Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis
PLOS ONE, 2018;
FI:2,766; Q1
The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concern
RHEUMATOLOGY INTERNATIONAL, 2018;
FI:1,952; Q4
The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concern (vol 38, pg 1735, 2018)
RHEUMATOLOGY INTERNATIONAL, 2018;
FI:1,952; Q4
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis
AMERICAN JOURNAL OF HUMAN GENETICS, 2017;
FI:9,025; D1
Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project
JOURNAL OF CLINICAL LIPIDOLOGY, 2017;
FI:5,812; D1
Increased expression of microRNA-155 in peripheral blood mononuclear cells from psoriasis patients is related to disease activity
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017;
FI:3,528; Q1
Influence of coronary artery disease and subclinical atherosclerosis related polymorphisms on the risk of atherosclerosis in rheumatoid arthritis
SCIENTIFIC REPORTS, 2017;
FI:4,259; Q1
Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2017;
FI:4,498; Q1
IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus
ANNALS OF THE RHEUMATIC DISEASES, 2016;
FI:12,384; D1
Influence of elevated-CRP level-related polymorphisms in non-rheumatic Caucasians on the risk of subclinical atherosclerosis and cardiovascular disease in rheumatoid arthritis
SCIENTIFIC REPORTS, 2016;
FI:5,228; Q1
Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry
RHEUMATOLOGY, 2016;
FI:4,524; Q1
Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis
PHARMACOGENOMICS JOURNAL, 2016;
FI:3,784; Q1
Tacrolimus-induced gynecomastia in a patient with polymyositis
MEDICINA CLINICA, 2016;
FI:1,267; Q2
Efectividad en la vida real de upadacitinib para el alivio temprano y sostenido del dolor en la espondiloartritis axial radiográfica (UPSTAND)
Financiador: ABBVIE SPAIN S.L.U.
Tipo de prueba: ESTUDIO OBSERVACIONAL CON MEDICAMENTO
Tiempo de ejecución: 16/03/2023 - 30/06/2025
IP: ENRIQUE RAYA ALVAREZ
Estudio de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de pegozafermina en pacientes con hipertrigliceridemia grave (HTGG). ENTRUST
Financiador: 89BIO INC
Tipo de prueba: ENSAYO CLÍNICO CON MEDICAMENTOS
Tiempo de ejecución: 12/09/2023 - 30/12/2024
IP: ISMAEL FRANCISCO AOMAR MILLAN
“Estudio prospectivo aleatorizado, multicéntrico, para comparar la eficacia a 52 semanas (1 año) de teriparatida biosimilar y alendronato en la prevención de nuevas fracturas vertebrales morfométricas y/o agravamiento de fracturas vertebrales previas en mujeres con fractura vertebral clínica o fractura de cadera reciente (riesgo inminente de fractura) y baja densidad mineral ósea. Estudio IMMINENT
Financiador: GEDEON RICHTER IBÉRICA S.A.
Tipo de prueba: ENSAYO CLINICO COMERCIAL
Tiempo de ejecución: 14/06/2022 - 30/12/2023
IP: ENRIQUE RAYA ALVAREZ
Un estudio multinacional, no intervencionista de tofacitinib en pacientes tratados para la artritis psoriásica. TOPSATI. PFI-TOF-2020-01
Financiador: PFIZER HOLDING FRANCE
Tipo de prueba: ESTUDIO OBSERVACIONAL CON MEDICAMENTO
Tiempo de ejecución: 03/08/2022 - 30/01/2024
IP: ENRIQUE RAYA ALVAREZ
Evaluación de guselkumab (Tremfya®) y el tratamiento con distintos inhibidores de la IL-17 en pacientes con artritis psoriásica en la práctica clínica habitual; estudio de cohortes, observacional y prospectivo.
Financiador: JANSSEN-CILAG INTERNATIONAL N.V.
Tipo de prueba: ESTUDIO POSAUTORIZACION COMERCIAL
Tiempo de ejecución: 19/11/2021 - 30/10/2027
IP: ENRIQUE RAYA ALVAREZ
PsA Biológicos: Estudio observacional retrospectivo sobre los patrones de tratamiento anti-IL17 en el manejo de la artritis psoriásica. LIL-IXE-2020-01 (LY2439821)
Financiador: LILLY, S.A.
Tipo de prueba: ESTUDIO POSAUTORIZACION COMERCIAL
Tiempo de ejecución: 06/10/2020 - 30/01/2021
IP: ENRIQUE RAYA ALVAREZ
Estudio observacional de la persistencia del tratamiento en la artritis psoriasica Estudio PRO-SPIRIT. (LIL-IXE-2019-01)
Financiador: ELI LILLY AND COMPANY
Tipo de prueba: ESTUDIO POSAUTORIZACION COMERCIAL
Tiempo de ejecución: 20/10/2020 - 30/12/2025
IP: ENRIQUE RAYA ALVAREZ